Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-I: ABT-450/r + ABT-267 in HCV GT1b and GT4
NCT01685203Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2012
- Primary completion
- Jun 2014
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of paritaprevir, ombitasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Aug 2012; status: completed.
02
Drugs
paritaprevirombitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01685203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685203.